[M$5k subsidy] Will any FDA-approved GLP-1 agonists be withdrawn from the market for safety reasons by...
Santé et médecineOne-Off3aManifold MarketsSans KYCDonnées de résolution vérifiéesAssez bien calibréPrévision communautaire actuelle2030 36.4%En tête parmi 6 options
Prévisionnistes
21
Type de question
multiple choice
Méthodologie
Play-money forecasting platform
Type de source
Prévision
Variation 7j
0.0 pts
Données du marché
Mis à jour il y a 10 heures
Obsolète18 nov. 23, 22:14 UTC1 janv. 30, 04:59 UTC
Tendances
Règles
Inspired by https://manifold.markets/AaronKaufman/will-any-fdaapproved-glp1-agonists and will use the same criteria:
- GLP-1 agonists, such as semaglutide (ozempic/wegovy), tirzepatide (mounjaro), and dulaglutide (Trulicity), are becoming popular for weight loss and Type-2 diabetes treatment.
- This market resolves positively if any approved GLP-1 agonists for either T2D or weight loss are withdrawn from the market due to safety reasons by the listed date.
- This applies either if the FDA mandates it or if the company withdraws the drug voluntarily.
